Vaccine prospects: Global distribution of covid vaccines has begun

Pfizer and BioNTech have worked on an mRNA vaccine to prevent COVID-19. Clinical trials in 44,000 people have shown the vaccine to be 95% effective in preventing COVID-19. The Pfizer-BioNTech vaccine has been authorized for emergency use by the FDA, and it is currently being distributed throughout the country in phases to those who are eligible.

Moderna is a Massachusetts-based biotech company working with the NIH. Their vaccine injects snippets of mRNA to mimic COVID.  

Clinical trials in 30,000 people have shown the Moderna vaccine to be 94.1% effective in preventing COVID-19. The Moderna vaccine has been authorized for emergency use by the FDA, and it is currently being distributed throughout the country in phases to those who are eligible.

Janssen Vaccines in Leiden collaborated with its parent company Janssen Pharmaceuticals in Belgium, a subsidiary of Johnson & Johnson, on producing a viral vector vaccine. When the viral vector enters our body, it produces a harmless part of the virus, called a spike protein, that is found on the surface of the virus that causes COVID-19. Our body recognizes the foreign protein and produces antibodies in response. The vaccine is 66.3% effective in preventing COVID-19 and is 100% effective against COVID-related hospitalization or death. It is currently being distributed throughout the country in phases to those who are eligible.